# EDGAR Filing Document

**Accession Number:** 0001562189
**File Stem:** 0001193805-25-001290
**Filing Date:** 2025-9
**Character Count:** 27468
**Document Hash:** ea89f2b47e461b884bfd509162f5fcfb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193805-25-001290.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001193805-25-001290

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20260130

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SINOVAC BIOTECH LTD
- **CENTRAL INDEX KEY:** 0001084201
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** B9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-79318
- **FILM NUMBER:** 26582968

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 39 SHANGDI XI ROAD
- **STREET 2:** HAIDIAN DISTRICT
- **CITY:** BEIJING
- **NON US STATE TERRITORY:** CHINA
- **PROVINCE COUNTRY:** F4
- **ZIP:** 100085
- **BUSINESS PHONE:** 86-10-82799800

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 39 SHANGDI XI ROAD
- **STREET 2:** HAIDIAN DISTRICT
- **CITY:** BEIJING
- **NON US STATE TERRITORY:** CHINA
- **PROVINCE COUNTRY:** F4
- **ZIP:** 100085

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NET FORCE SYSTEMS INC
- **DATE OF NAME CHANGE:** 19991110
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 1Globe Capital LLC
- **CENTRAL INDEX KEY:** 0001562189

**ORGANIZATION NAME:**
- **EIN:** 800841812
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 333 PROVIDENCE HIGHWAY
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02062
- **BUSINESS PHONE:** 5148398866

**MAIL ADDRESS:**
- **STREET 1:** 333 PROVIDENCE HIGHWAY
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02062

## Exhibit 99.5

Exhibit 99.5

**<u>JOINT FILING AGREEMENT</u>**

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Shares, par value $0.001 per share, of Sinovac Biotech Ltd., a corporation organized under the laws of Antigua and Barbuda. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

---

| | |
|:---|:---|
| 1Globe Capital LLC | 1Globe Capital LLC |
| By: | /s/ Jiaqiang Li |
|  | Jiaqiang Li, Chairman |
| Date: | 09/12/2025 |

---

---

| | |
|:---|:---|
| 1Globe Biomedical (Hong Kong) Company Limited | 1Globe Biomedical (Hong Kong) Company Limited |
| By: | /s/ Jiaqiang Li |
|  | Jiaqiang Li, Chairman |
| Date: | 09/12/2025 |

---

---

| | |
|:---|:---|
| Jiaqiang Li | Jiaqiang Li |
| By: | /s/ Jiaqiang Li |
|  | Jiaqiang Li |
| Date: | 09/12/2025 |

---

### Attached PDF Documents

**Attachment 1:** `ex991to13da714598002_091225.pdf`

_No text found in this document._

**Attachment 2:** `ex992to13da714598002_091225.pdf`

_No text found in this document._

**Attachment 3:** `ex993to13da714598002_091225.pdf`

_No text found in this document._

**Attachment 4:** `ex994to13da714598002_091225.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**SINOVAC BIOTECH LTD**

*(Name of Issuer)*

**Common Shares, par value $0.001 per share**

*(Title of Class of Securities)*

**P8696W104**

*(CUSIP Number)*

**1GLOBE CAPITAL LLC**<br>One International Place, 44th Fl<br>Boston MA 02110<br>617-649-1157

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **P8696W104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**1Globe Capital LLC** | Name of reporting person<br>**1Globe Capital LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6812855.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11702460.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6812855.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11702460.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**18515315.00** | Aggregate amount beneficially owned by each reporting person<br>**18515315.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**32.3%** | Percent of class represented by amount in Row (11)<br>**32.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** This Amendment No. 7 to Schedule 13D, or this Amendment, is being filed by 1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li (each referred to herein as a reporting person, or together, referred to herein as the reporting persons) relating to the common shares, par value $0.001 per share, or the Common Shares, of Sinovac Biotech Ltd., the Issuer, a corporation organized under the laws of Antigua and Barbuda. This Amendment amends and supplements the statement on Schedule 13D (as amended, referred to herein as the Schedule 13D) originally filed with the U.S. Securities and Exchange Commission, or the SEC, on July 7, 2017, as amended from time to time.

| **CUSIP No.** | **P8696W104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**1Globe Biomedical (Hong Kong) Company Limited** | Name of reporting person<br>**1Globe Biomedical (Hong Kong) Company Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**HONG KONG** | Citizenship or place of organization<br>**HONG KONG** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6812855.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11702460.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6812855.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11702460.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**18515315.00** | Aggregate amount beneficially owned by each reporting person<br>**18515315.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**32.3%** | Percent of class represented by amount in Row (11)<br>**32.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** This Amendment No. 7 to Schedule 13D, or this Amendment, is being filed by 1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li (each referred to herein as a reporting person, or together, referred to herein as the reporting persons) relating to the common shares, par value $0.001 per share, or the Common Shares, of Sinovac Biotech Ltd., the Issuer, a corporation organized under the laws of Antigua and Barbuda. This Amendment amends and supplements the statement on Schedule 13D (as amended, referred to herein as the Schedule 13D) originally filed with the U.S. Securities and Exchange Commission, or the SEC, on July 7, 2017, as amended from time to time.

| **CUSIP No.** | **P8696W104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jiaqiang Li** | Name of reporting person<br>**Jiaqiang Li** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CHINA** | Citizenship or place of organization<br>**CHINA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6812855.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**11702460.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6812855.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**11702460.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**18515315.00** | Aggregate amount beneficially owned by each reporting person<br>**18515315.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**32.3%** | Percent of class represented by amount in Row (11)<br>**32.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** This Amendment No. 7 to Schedule 13D, or this Amendment, is being filed by 1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li (each referred to herein as a reporting person, or together, referred to herein as the reporting persons) relating to the common shares, par value $0.001 per share, or the Common Shares, of Sinovac Biotech Ltd., the Issuer, a corporation organized under the laws of Antigua and Barbuda. This Amendment amends and supplements the statement on Schedule 13D (as amended, referred to herein as the Schedule 13D) originally filed with the U.S. Securities and Exchange Commission, or the SEC, on July 7, 2017, as amended from time to time.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, par value $0.001 per share

**(b) Name of Issuer:**
SINOVAC BIOTECH LTD

**(c) Address of Issuer's Principal Executive Offices:**
NO. 39 SHANGDI XI ROAD, HAIDIAN DISTRICT, BEIJING, F4, 100085

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

On July 25, 2025, Vivo Capital Surplus Fund VIII, L.P. ("Vivo Fund VIII") filed an amended complaint (the "Amended Complaint") with the U.S. District Court for the Commonwealth of Massachusetts in the civil action initiated by Vivo Fund VIII on April 14, 2025 and previously disclosed in Amendment No. 6 to the Schedule 13D (the "Vivo Action").  In the Amended Complaint, Vivo Fund VIII alleges a disclosure violation claim under Section 13(d) of the Securities Exchange Act of 1934, repeating in a single count the allegations that appeared in its original complaint.  Among other things, Vivo Fund VIII alleges that (1) Dr. Li has not filed a Schedule 13D and as a result investors do not know how many Sinovac shares he beneficially owns; (2) 1Globe Capital LLC disclaims in its Schedule 13D Amendments any "arrangement" or "agreement" with OrbiMed Advisors LLC and OrbiMed Capital LLC (collectively, "OrbiMed"), but has not disclosed whether it and OrbiMed have any "understandings" or "relationship"; and (3) the Schedule 13D Amendments include no disclosure regarding defendants and OrbiMed's "ongoing plans and proposals to regain their control of Sinovac," now that Vivo Fund VIII alleges that there was a change in control at the Special Meeting (as defined and discussed below).  The foregoing summary of the Amended Complaint does not purport to be complete and is qualified in its entirety by the full copy of the Amended Complaint, which is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

1Globe Capital LLC and Dr. Li dispute Vivo Fund VIII's claim and intend to vigorously defend against it. On August 15, 2025, 1Globe Capital LLC and Dr. Li filed a motion to dismiss the Amended Complaint and motion to dissolve the preliminary injunction (the "Motion to Dismiss") and a brief in support of the foregoing motion (the "Brief in Support of Motion to Dismiss") entered by the Court in the Vivo Action and previously disclosed in Amendment No. 6 to the Schedule 13D.  The Brief in Support of Motion to Dismiss explains that the Vivo Action is without basis, Vivo Fund VIII lacks standing to bring the Vivo Action, the Vivo Action has been rendered moot by the reporting persons' subsequent Schedule 13D filings, and the Vivo Action has been maintained solely for the purpose of harassing the current Board installed by the Privy Council's Order and per Antiguan law following the non-appealable ruling by the Privy Council. The foregoing summaries of Motion to Dismiss and the Brief in Support of Motion to Dismiss do not purport to be complete and are qualified in their entirety by the full copies of the Brief in Support of Motion to Dismiss and the Motion to Dismiss, which are attached hereto as Exhibits 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

On August 29, 2025, Vivo Fund VIII filed a memorandum in opposition to the Motion to Dismiss.

On September 10, 2025, 1Globe Capital LLC and Dr. Li filed a reply to the memorandum in opposition to the Motion to Dismiss filed by Vivo Fund VIII (the "Reply to Vivo"). A copy of the Reply to Vivo is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

On July 8, 2025, the Issuer opened and validly adjourned its Special Meeting of Shareholders (the "Special Meeting"), in light of the Disputed PIPE Action (as defined below). Immediately after the Special Meeting was validly adjourned, counsel representing SAIF Partners IV L.P. ("SAIF"), Advantech Capital Partners Ltd., Prime Success, L.P. and Vivo Capital LLC (collectively, the "Dissenting Investor Group") purported to organize a continuation of the Special Meeting on a minibus at an unannounced location and time where an alleged "new" Board was elected (the "New Imposter Board") without required quorum and without a notice to the incumbent Board or to any other shareholders. According to the Dissenting Investor Group, Dr. Li was elected as one of the directors of the Issuer. The reporting persons do not believe the New Imposter Board has been validly elected and support the current Board installed by the Privy Council's Order and per Antiguan law.

On August 11, 2025, the Issuer, 1Globe Capital LLC and OrbiMed Partners Master Fund Limited (collectively, the "Claimants") filed a statement of claim (the "Antigua SSM Claim") with the Eastern Caribbean Supreme Court in the High Court of Justice against SAIF and each of the members of the New Imposter Board (other than Dr. Li) (the "Antigua SSM Action"), challenging the purported continuation of the Special Meeting and the purported appointment of the New Imposter Board. Pursuant to the Antigua SSM Action, the Claimants are seeking declarations that the purported appointments of each member of the New Imposter Board at the invalid continuation of the Special Meeting were invalid and of no effect and that the purported continuation of the Special Meeting by the Dissenting Investor Group and each of the resolutions purportedly passed there at were invalid and of no effect. The Antigua SSM Action is currently pending.

The Claimants have also filed a statement of claim (the "Disputed PIPE Claim") with the Eastern Caribbean Supreme Court in the High Court of Justice against Vivo Capital LLC, Vivo Fund VIII, Vivo Capital Surplus Fund VIII, L.P., Vivo Capital Fund IX, L.P., Prime Success, L.P. and Cede & Co. (the "Disputed PIPE Action"). Among other items, the Disputed PIPE Action challenges the validity of the Disputed PIPE (as defined in Amendment No. 2 to the Schedule 13D), and seeks a declaration that the Common Shares issued under the Disputed PIPE be set aside and a rectification of the Issuer's register of shareholders to delete any entries in respect of certain of the purported allotments and transfers of the Common Shares issued under the Disputed PIPE. The Disputed PIPE Claim was filed on May 6, 2025 and is currently pending.

The reporting persons purchased the securities of the Issuer reported herein based on the reporting persons' belief that the securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the reporting persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the reporting persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the reporting persons may deem advisable.

Other than in Dr. Li's capacity as the Chairman of the Board, no reporting person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein; however, the reporting persons, at any time and from time to time, may review, reconsider and change their intention with respect to any and all matters referred to in Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:

The aggregate percentage of Common Shares reported owned by each person named herein is based on 57,281,861 Common Shares outstanding as of December 31, 2017, as reported in the Issuer's Form 20-F filed with the SEC on May 11, 2018. As described herein and in Amendment No. 2 to the Schedule 13D, the issuance by the Issuer of the Exchange Shares (as defined in the Issuer's Form 20-F filed with the SEC on April 29, 2019) and the Disputed PIPE, among other things, are the subject of ongoing litigation, and therefore the Common Shares outstanding used herein does not include Common Shares purportedly issued after May 2018.

The information set forth on the applicable cover page hereto is incorporated herein by reference. The reporting persons beneficially own an aggregate of 18,515,315 shares, or approximately 32.3% of the Issuer's outstanding Common Shares, consisting of (i) 6,812,855 Common Shares held directly by the reporting person 1Globe Capital LLC and which may be deemed indirectly beneficially owned by 1Globe Biomedical (Hong Kong) Company Limited, as the sole member of 1Globe Capital LLC, (ii) the Subject Shares (as defined in the Schedule 13D) held by CDH Utopia Limited and (iii) 5,702,460 Common Shares held by relatives of Dr. Li (the "Relative Shares"), which are included herein pursuant to the order issued by the SEC on Release No. 88864 in connection with administrative proceeding File No. 3-19799. The Subject Shares held by CDH Utopia Limited include 3,459,763 Common Shares previously held by Chiang Li Family reported in the Schedule 13G filed on April 11, 2016. Those shares dropped below the 5% reporting threshold in 2018 and 2019 due to the changes in the total shares outstanding of the Issuer and were subsequently acquired by 1Globe Biomedical (Hong Kong) Company Limited and immediately sold to CDH Utopia Limited as reported in the Schedule 13D amendment filed on December 21, 2020. Dr. Li may be deemed the ultimate beneficial owner of the Common Shares held by 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited, as he directly or indirectly exercises sole voting and dispositive power over such shares as Chairman of each entity. 1Globe Biomedical (Hong Kong) Company Limited possesses voting rights in 70% of the Subject Shares as well as certain financial upside for the total 6,000,000 Common Shares which are held by CDH Utopia Limited and, in such capacities, Dr. Li may be deemed to beneficially own the shares of the Issuer owned by such entities.

The inclusion of the Subject Shares and the Relative Shares on this Schedule 13D shall not be construed as an admission that the reporting persons are the beneficial owners of such Common Shares. Each of the reporting persons disclaims beneficial ownership over any Common Shares not directly owned by him or it.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows:

The aggregate percentage of Common Shares reported owned by each person named herein is based on 57,281,861 Common Shares outstanding as of December 31, 2017, as reported in the Issuer's Form 20-F filed with the SEC on May 11, 2018. As described herein and in Amendment No. 2 to the Schedule 13D, the issuance by the Issuer of the Exchange Shares and the Disputed PIPE, among other things, are the subject of ongoing litigation, and therefore the Common Shares outstanding used herein does not include Common Shares purportedly issued after May 2018.

The information set forth on the applicable cover page hereto is incorporated herein by reference. The reporting persons beneficially own an aggregate of 18,515,315 shares, or approximately 32.3% of the Issuer's outstanding Common Shares, consisting of (i) 6,812,855 Common Shares held directly by the reporting person 1Globe Capital LLC and which may be deemed indirectly beneficially owned by 1Globe Biomedical (Hong Kong) Company Limited, as the sole member of 1Globe Capital LLC, (ii) the Subject Shares held by CDH Utopia Limited and (iii) the Relative Shares held by relatives of Dr. Li, which are included herein pursuant to the order issued by the SEC on Release No. 88864 in connection with administrative proceeding File No. 3-19799. The Subject Shares held by CDH Utopia Limited include 3,459,763 Common Shares previously held by Chiang Li Family reported in the Schedule 13G filed on April 11, 2016. Those shares dropped below the 5% reporting threshold in 2018 and 2019 due to the changes in the total shares outstanding of the Issuer and were subsequently acquired by 1Globe Biomedical (Hong Kong) Company Limited and immediately sold to CDH Utopia Limited as reported in the Schedule 13D amendment filed on December 21, 2020. Dr. Li may be deemed the ultimate beneficial owner of the Common Shares held by 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited, as he directly or indirectly exercises sole voting and dispositive power over such shares as Chairman of each entity. 1Globe Biomedical (Hong Kong) Company Limited possesses voting rights in 70% of the Subject Shares as well as certain financial upside for the total 6,000,000 Common Shares which are held by CDH Utopia Limited and, in such capacities, Dr. Li may be deemed to beneficially own the shares of the Issuer owned by such entities.

The inclusion of the Subject Shares and the Relative Shares on this Schedule 13D shall not be construed as an admission that the reporting persons are the beneficial owners of such Common Shares. Each of the reporting persons disclaims beneficial ownership over any Common Shares not directly owned by him or it.

**(c)**
(c) Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows:

No reporting person has engaged in transactions in securities of the Issuer during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

The disclosure set forth in Item 4 of the Schedule 13D, as amended, is incorporated herein by reference.

On September 12, 2025, the reporting persons entered into a Joint Filing Agreement (the "Joint Filing Agreement") pursuant to which the reporting persons agreed to the joint filing of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.5 and is incorporated herein by reference.

Other than as described herein and previously set forth in the Schedule 13D, there are no contracts, arrangements, understandings or relationships among the reporting persons, or between the reporting persons and any other person, with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** 1Globe Capital LLC

**Signature:** /s/ Jiaqiang Li

**Name/Title:** Jiaqiang Li, Chairman

**Date:** 09/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** 1Globe Biomedical (Hong Kong) Company Limited

**Signature:** /s/ Jiaqiang Li

**Name/Title:** Jiaqiang Li, Chairman

**Date:** 09/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jiaqiang Li

**Signature:** /s/ Jiaqiang Li

**Name/Title:** Jiaqiang Li

**Date:** 09/12/2025